SGLT2 inhibitors helps to protect against cancer therapy-induced cardiovascular toxicity with cardioprotective effects against anthracycline exposure [288], and anti-cancer drug ponatinib-induced cardiotoxicity [289]. The gene discussed is SLC5A2; the disease is cancer.